By Fineline Cube Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Polpharma Biologics announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to ocrelizumab, upon regulatory approval.
Deal Structure & Territory
| Component | Detail |
|---|---|
| Parties | Teva Pharmaceutical Industries Ltd.; Polpharma Biologics |
| Product | Ocrelizumab biosimilar (intravenous and subcutaneous formulations) |
| License Type | Exclusive commercialization rights |
| Territory | United States, Europe, Brazil, Canada, Australia, New Zealand, Israel, Turkey |
| Announcement Date | 09 Jul 2026 |
| Development Status | Under development by Polpharma Biologics |
This strategic partnership leverages Teva’s extensive global commercial infrastructure with Polpharma Biologics’ specialized biosimilar development expertise in one of the most valuable biologic franchises.
Product Profile & Market Context
- Reference Product: Ocrelizumab (Ocrevus®), developed by Roche’s Genentech
- Mechanism: Humanized monoclonal antibody targeting CD20-positive B cells
- Indications: Relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS)
- Market Size: Global ocrelizumab sales exceeded $5.6 billion in 2025
- Patent Expiry: Key patents expire in major markets between 2026-2028
Ocrelizumab represents one of the most successful multiple sclerosis therapies ever launched, making it a highly attractive target for biosimilar development. The availability of both intravenous and subcutaneous formulations addresses evolving patient and provider preferences for administration convenience.
Strategic Partnership Dynamics
Polpharma Biologics Responsibilities
- Development: Full responsibility for clinical and regulatory development activities
- Manufacturing: Complete control over manufacturing processes and supply chain
- Technical Expertise: Leveraging proven biosimilar development platform
- Quality Systems: Maintaining GMP-compliant manufacturing facilities
Teva Responsibilities
- Regulatory Submissions: Leading regulatory filing strategy in licensed territories
- Commercialization: Full commercial responsibility upon approval
- Market Access: Payer negotiations and reimbursement strategy
- Distribution: Leveraging existing specialty pharmaceutical distribution network
This division of responsibilities optimizes each partner’s core competencies while ensuring efficient development and commercial execution.
Market Impact & Competitive Landscape
| Aspect | Current Market | Biosimilar Impact |
|---|---|---|
| MS Treatment Cost | High-cost biologic therapy ($70,000-$90,000 annually) | Significant cost reduction potential |
| Patient Access | Limited by high co-pays and formulary restrictions | Improved access through lower pricing |
| Healthcare Systems | Substantial budget impact on payers | Reduced burden on healthcare budgets |
| Innovation Incentive | Premium pricing supports R&D investment | Balanced approach to innovation and access |
The introduction of ocrelizumab biosimilars is expected to generate substantial savings for healthcare systems while expanding treatment access for MS patients globally.
Commercial Implications
- Revenue Potential: Multi-billion dollar opportunity across licensed territories
- Pricing Strategy: Expected 15-30% discount to reference product pricing
- Market Share: Potential to capture significant share in competitive MS biosimilar market
- Launch Timing: Dependent on regulatory approval timelines in key markets
- Competitive Positioning: First-mover advantage in certain territories possible
Teva’s established presence in neurology and multiple sclerosis markets provides strong foundation for successful ocrelizumab biosimilar launch.
Strategic Significance
- Portfolio Enhancement: Strengthens Teva’s growing biosimilars portfolio in high-value therapeutic areas
- Neurology Leadership: Reinforces Teva’s position as leading MS therapy provider
- Global Expansion: Extends Polpharma Biologics’ reach beyond traditional European markets
- Biosimilar Expertise: Validates Polpharma Biologics’ capabilities in complex monoclonal antibody biosimilars
- Healthcare Value: Supports broader mission of improving access to essential biologic therapies
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, commercial launches, and market expectations. Actual results may differ due to risks including regulatory decisions, competitive dynamics, and market acceptance.-Fineline Info & Tech